Zentalis Pharmaceuticals (ZNTL) Change in Acquisitions & Divestments (2020 - 2026)

Zentalis Pharmaceuticals has reported Change in Acquisitions & Divestments for 7 years, with the latest figure at $60.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments changed 0.0% year-over-year to $60.0 million; the trailing twelve-month figure through Mar 2026 stood at $250.0 million (down 3.66% YoY), and the FY2025 full-year result was $250.0 million, down 7.82% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $60.0 million, down from $232.1 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $232.1 million in Q4 2025, with the low at -$307.3 million in Q4 2022.
• Average Change in Acquisitions & Divestments over 5 years is $63.9 million, with a median of $71.5 million recorded in 2024.
• Year-over-year, Change in Acquisitions & Divestments sank 338.79% in 2022 and surged 251.25% in 2023.
• Tracing ZNTL's Change in Acquisitions & Divestments over 5 years: stood at -$307.3 million in 2022, then jumped by 117.61% to $54.1 million in 2023, then surged by 32.16% to $71.5 million in 2024, then soared by 224.68% to $232.1 million in 2025, then sank by 74.15% to $60.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $60.0 million (Q1 2026), $232.1 million (Q4 2025), and -$112.1 million (Q3 2025), per Business Quant data.

Peer Comparison